| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CONSENSUS STATEMENT |
1 University of California, Los Angeles, CA, USA
2 Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
3 Medizinische Klinik III, Friedrich Alexander Universität, Erlangen, Germany
4 Abteilung für Rhumatologie, Universitätsklinik für Innere Medizin III, Wien, Austria
5 Medizinische Klinik III, Friedrich Alexander Universität, Erlangen, Germany
6 Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands
7 Department of Rheumatology and Clinical Immunology, Charité Hospital, Berlin, Germany
8 New York University School of Medicine, New York, NY, USA
9 Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada
10 Division of Rheumatology, University of California, San Diego, La Jolla, CA, USA
11 Rheumatology Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
Correspondence to:
Correspondence to:
Dr D E Furst, 1000 Veteran Avenue Rehabilitation Center, Room 32–5, Los Angeles, CA 90024, USA;
defurst@mednet.ucla.edu
Keywords: tumour necrosis factor 
; blocking agents; rheumatoid arthritis; biological agents
Abbreviations: aCL, anticardiolipin antibody; ACR, American College of Rheumatology; ANA, antinuclear antibody; DAS, disease activity score; DMARD, disease modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire disease index; IL, interleukin; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor; VAS, visual analogue scale
| The first 150 words of the full text of this article appear below. |
A s in previous years, the consensus group to consider the use of biological agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with universities in the United States, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference.
The 158 rheumatologists and bioscientists from 22 countries who attended the consensus conference were chosen from a worldwide group of people felt to have experience or interest in the use of biological agents for the treatment of rheumatoid arthritis (RA) and other rheumatic diseases. Unfortunately, the number of attendees and participants was limited so that not everyone who might have been appropriate could be invited.
Additional information has come to light in the past
This article has been cited by other articles:
|
|
 |
|
  P L C M van Riel, B Freundlich, D MacPeek, R Pedersen, J R Foehl, A Singh, and on behalf of ADORE study investigators Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial Ann Rheum Dis, August 1, 2008; 67(8): 1104 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bombardieri, A. A. Ruiz, P. Fardellone, P. Geusens, F. McKenna, K. Unnebrink, U. Oezer, S. Kary, H. Kupper, G. R. Burmester, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology, July 1, 2007; 46(7): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Leeb, I. Andel, J. Sautner, T. Nothnagl, and B. Rintelen The DAS28 in rheumatoid arthritis and fibromyalgia patients Rheumatology, December 1, 2004; 43(12): 1504 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F C Breedveld and J R Kalden Appropriate and effective management of rheumatoid arthritis Ann Rheum Dis, June 1, 2004; 63(6): 627 - 633. [Abstract] [Full Text]
|
|
|
|
|
|
P Sidiropoulos, G Bertsias, H D Kritikos, H Kouroumali, K Voudouris, and D T Boumpas Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit Ann Rheum Dis, February 1, 2004; 63(2): 144 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, M Dougados, P Emery, A Gibofsky, A F Kavenaugh, E C Keystone, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) Ann Rheum Dis, November 1, 2003; 62(90002): ii2 - 9. [Full Text] [PDF]
|
|
|
|
|
|
M C Hochberg, J K Tracy, M Hawkins-Holt, and R H Flores Comparison of the efficacy of the tumour necrosis factor {alpha} blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Ann Rheum Dis, November 1, 2003; 62(90002): ii13 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Flendrie, M C W Creemers, P M J Welsing, A A den Broeder, and P L C M van Riel Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis Ann Rheum Dis, November 1, 2003; 62(90002): ii30 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Braun, J Sieper, and D van der Heijde Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal Ann Rheum Dis, October 1, 2003; 62(10): 1023 - 1024. [Full Text]
|
|
|
|
|
|
J Braun, T Pham, J Sieper, J Davis, S. van der Linden, M Dougados, and D van der Heijde International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis, September 1, 2003; 62(9): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
